Conventional MRI features of adult diffuse glioma molecular subtypes: a systematic review

[1] Louis DN(2016)The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary Acta Neuropathol 131 803-820

[2] Perry A(2009)IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765-773

[3] Reifenberger G(2018)cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” Acta Neuropathol 136 805-810

[4] von Deimling A(2019)Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria Neuro-Oncology 22 515-523

[5] Figarella-Branger D(2015)Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials Neuro-Oncology 17 1188-1198

[6] Cavenee WK(2018)Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice Eur Radiol 28 3306-3317

[7] Ohgaki H(2017)Imaging Correlates of Adult Glioma Genotypes Radiology 284 316-331

[8] Wiestler OD(2018)Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement JAMA 319 388-396

[9] Kleihues P(2011)QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies Ann Intern Med 155 529-536

[10] Ellison DW(2014)Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms Oncol Lett 7 1895-1902

[1] Louis DN(2016)The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary Acta Neuropathol 131 803-820

[2] Perry A(2009)IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765-773

[3] Reifenberger G(2018)cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” Acta Neuropathol 136 805-810

[4] von Deimling A(2019)Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria Neuro-Oncology 22 515-523

[5] Figarella-Branger D(2015)Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials Neuro-Oncology 17 1188-1198

[6] Cavenee WK(2018)Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice Eur Radiol 28 3306-3317

[7] Ohgaki H(2017)Imaging Correlates of Adult Glioma Genotypes Radiology 284 316-331

[8] Wiestler OD(2018)Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement JAMA 319 388-396

[9] Kleihues P(2011)QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies Ann Intern Med 155 529-536

[10] Ellison DW(2014)Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms Oncol Lett 7 1895-1902